Ibrutinib/Imbruvica brings hope to stem cell transplant patients with chronic graft-versus-host-disease

Ibrutinib/Imbruvica brings hope to stem cell transplant patients with chronic graft-versus-host-disease

'FDA granted a fourth Breakthrough Therapy Designation (BTD) for ibrutinib (IMBRUVICA®) as a potential treatment of chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy. The FDA also granted the therapy Orphan Drug Designation for the condition. cGVHD is a severe and potentially life-threatening condition in which transplanted cells from the donor attack the patient's body. Patients may develop this common complication after undergoing allogeneic stem cell or bone marrow transplantation in which they receive cells from a donor. There are currently no therapies specifically approved for this condition. Most patients with cGVHD are prescribed glucocorticoids, a systemic steroid treatment that is able to act upon cells throughout the entire body; however, research shows that long-term use of steroids can lead to serious health complications.'

prnewswire.com/news-release...

Neil

3 Replies

oldestnewest
  • This is so exciting for AML and ALL patients who ofter have no hope except a transplant!

  • we are looking hard at this, thanks so much for the pointer!

  • A Dana-Farber Cancer Institute study published in the New England Journal of Medicine, suggests that a new treatment approach, using repeated doses of the immunotherapy drug ipilimumab, can restore a complete remission for some stem cell transplant patients that experience a relapse:

    sciencedaily.com/releases/2...

You may also like...